InvestorsHub Logo
Followers 3
Posts 607
Boards Moderated 0
Alias Born 06/07/2010

Re: Paulieme post# 1079

Tuesday, 02/07/2017 10:03:22 PM

Tuesday, February 07, 2017 10:03:22 PM

Post# of 6315
Referring to CT order-"It means they have really obtained something very substantial,to the point the can have it excluded from disclosing."(refers to the 8K filing on 1/13/17 Nemus yesterday recorded a confidential order that was granted by the SEC called a CT Order, Confidential Treatment Order: It is recorded at the SEC as of February 6, 2017:

CT ORDER -- Documents -- Confidential treatment order
Acc-no: 9999999997-17-000586 (34 Act) Size: 11 KB 2017-02-06 000-55136 17576344

You can find it here:
https://www.sec.gov/Archives/edgar/data/1516551/999999999717000586/filename1.pdf

Inside the confidential treatment order it refers to the 8K filing on 1/13/2017 which you can find below and the pdf further states that "Nemus Bioscience, Inc. submitted an application under Rule 24b-2 REQUESTING CONFIDENTIAL TREATMENT FOR INFORMATION IT EXCLUDED FROM THE EXHIBIT to a Form 8-K filed on
January 13, 2017.... through January 10, 2027" (FOR THE NEXT TEN YEARS) which means they have really obtained something very substantial to the point the can have it excluded from disclosing. That, my friends, is very rare.

Here is the 8K filing it was excluded from:
https://www.sec.gov/Archives/edgar/data/1516551/000164033417000091/nmus_8k.htm
On January 10, 2017, Nemus Bioscience, Inc. (the “Company”) entered into a license agreement (the “License Agreement”) with the University of Mississippi, School of Pharmacy (“UM”), pursuant to which UM granted the Company an exclusive, perpetual license, including the right to sublicense, under intellectual property related to UM5070, a platform of cannabinoid-based molecules to research, develop and commercialize products for the treatment of infectious diseases. The License Agreement culminates roughly one year of screening and target molecule identification studies especially focused on therapy-resistant infectious organisms like methicillin-resistant Staphylococcus aureus (MRSA). (So it must really be something special to exclude it for ten years and apparently more important that this MRSA therapy they DID disclose.)

It's definitely a good thing. Truly a case of when no news is good news /2017)! (This,thanks to Gee, yahoo conversation board)!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SKYE News